IPO

About the Company: Park Medi is the second largest private hospital chain in North India with an aggregate bed capacity of ~3,250 beds, including 870 ICU beds, as well as 67 OTs and two dedicated cancer units. The Company operate a network of 14 multi-super specialty hospitals under the Park' brand. Park Medi has 8...

IPO Note - Corona Remedies Limited Corona Remedies Limited is an India-focused branded pharma firm, develops, manufactures, and markets 71 brands across women's healthcare, cardio-diabeto, pain management, urology, and more

IPO Note - Wakefit Innovations Limited Over the years, Wakefit Innovations Ltd. has evolved from a sleep solutions player into a one-stop destination offering home and furnishing solutions to meet customers' evolving needs, with products tailored to cater to the mass, masstige, and premium segments

ICICI Prudential Asset Management Company Ltd. (ICICIPru) is one of the oldest asset management companies (AMC) in India with a strong parentage of ICICI Bank and Prudential Corporation Holding Ltd. ICICIPru is also the largest AMC in India in terms of active mutual fund Quarterly Average Assets Under Management (QAAUM) and Equity & Equity-oriented QAAUM with a market share of 13.3% and 13.6% as of Sep'25, respectively. The total mutual fund QAAUM stood at Rs 10.1 tn as of same date which is second only to SBI MF. Equity and Equity-oriented schemes contribute ~56% of its total MF...

Park Medi World Ltd. (PMWL) ranks as the second largest private hospital chain in North India with an aggregate bed capacity of 3,000 beds as of FY25. PMWL operates a network of 14 NABH accredited multi-super specialty hospitals under the Park' brand. It offers over 30 super specialty and specialty services including internal medicine, neurology, urology, gastroentereology general surgery, orthopedics and oncology. As of Sep'25, PMWL had a dedicated team of 1,014...

Nephrocare Health Services Ltd. (NHSL) is a dialysis services provider which offers comprehensive dialysis care through its network of clinics from diagnosis to treatment and wellness programs including haemodialysis, home and mobile dialysis, supported by pharmacy. In FY25, the company served 29,281 patients and completed 28,85,450 treatments in India which represented ~10% of the total dialysis patients in India. NHSL is India's only dialysis services provider with an international presence having a network of 51 clinics across the Philippines, Uzbekistan and Nepal as of Sep'25. The...

formulation company engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. Company is the fastest growing company among the top 30 companies in the Indian Pharmaceutical Market (IPM) in terms of domestic sales in the IPM, between MAT June 2024 and MAT June 2025. During this period, company's domestic sales grew at a CAGR of 13.58% compared to the IPM which grew at a CAGR of...

The primary market will be busy this week with 14 new issues, including nine from the SME segment. Eleven companies are also set to list on the exchanges, following eleven debuts last week.

The company has undertaken recent acquisitions like Myoril from Sanofi and Spye from Bayer. It is bolstering its gynaecology and cardiology portfolio and executed a partnership with Ferring for Solifenacin.

The company’s future strategy hinges on a multi-pronged approach of product innovation, physical retail expansion, and brand enhancement to capitalize on favorable industry trends and solidify its market leadership.